The firm says the shares have been down recently on competitive concerns from NewAmsterdam’s (NAMS) CETP inhibitor, obicetrapib, which recently had positive Phase 3 data. However, investors are ...
NewAmsterdam Pharma’s cardio drug succeeded in a third readout this year, showing that obicetrapib could lower a type of lipoprotein that carries cholesterol in the … ...
may reflect nuggets of cardiovascular outcomes results that NewAmsterdam included in its readout on the CETP inhibitor. After one year, the biotech saw a 21% drop in major adverse cardiovascular ...
Obicetrapib’s safety profile, including its potential impact on blood pressure — a concern for drugs of its kind, known as CETP inhibitors — were also comparable to a placebo. A higher percentage of ...
MANILA, Philippines — Due to an alleged conflict of interest, a group of seafarers has asked Department of Migrant Workers (DMW) Assistant Secretary Jerome Pampolina to inhibit from drafting the ...
A SEAFARER'S group urged on Saturday an official of the Department of Migrant Workers (DMW) to inhibit himself from drafting the implementing rules and regulations (IRR) of the Magna Carta of Filipino ...
Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, P. R. China School of Traditional Chinese ...
Obicetrapib is a selective inhibitor of cholesteryl ester transfer protein (CETP). By blocking CETP, these inhibitors work to increase high-density lipoprotein (HDL) cholesterol and lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback